9-Oxaergoline
pharmaceutical compound
9-Oxaergoline is a low-potency dopamine receptor agonist related to the ergolines. It is the analogue and bioisostere of ergoline in which the carbon atom at the 9 position of the ergoline ring system has been replaced with an oxygen atom. A few notable derivatives of 9-oxaergoline have been studied and characterized, including RU-29717 (N-propyl-9-oxaergoline), 6-ethyl-9-oxaergoline (EOE), and voxergolide (RU-41656), which are all substantially more potent as dopamine receptor agonists than 9-oxaergoline itself. Other derivatives, such as N-methyl-9-oxaergoline, have been characterized as well. In addition to its dopaminergic activity, RU-29717 is notable in also having affinity for serotonin receptors and in producing a short-lasting head-twitch response in rodents. The head-twitch response is notable in being a behavioral proxy of psychedelic effects caused by serotonin 5-HT2A receptor agonism. The potential serotonergic activities of 9-oxaergoline and N-methyl-9-oxaergoline do not appear to have been reported.
This brief starts where responsible research should: with the source description of “9-Oxaergoline” as pharmaceutical compound. Everything that follows is an evidence route, not borrowed authority.
Why this record matters
The subject matters to the general reference register because the source frames it as pharmaceutical compound. Its deeper value depends on whether names, dates, institutions and citations support that framing.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Aug 17, 2026. The linked authority identifier is Q139964033. None of the 0 selected statements returned an explicit reference.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “9-Oxaergoline”, its source revision and the description used here.
- Expand the search: follow 9-Oxaergoline primary sources, 9-Oxaergoline archive and 9-Oxaergoline research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “9-Oxaergoline”?
- Which cited source is closest to the event, object or claim?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “9-Oxaergoline” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.